NZ509729A - Agents with an antidepressive effect - Google Patents

Agents with an antidepressive effect

Info

Publication number
NZ509729A
NZ509729A NZ509729A NZ50972999A NZ509729A NZ 509729 A NZ509729 A NZ 509729A NZ 509729 A NZ509729 A NZ 509729A NZ 50972999 A NZ50972999 A NZ 50972999A NZ 509729 A NZ509729 A NZ 509729A
Authority
NZ
New Zealand
Prior art keywords
agents
antidepressive effect
antidepressive
effect
pramipexole
Prior art date
Application number
NZ509729A
Other languages
English (en)
Inventor
Jerzy Maj
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NZ509729A publication Critical patent/NZ509729A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ509729A 1998-07-07 1999-07-02 Agents with an antidepressive effect NZ509729A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung
PCT/EP1999/004595 WO2000002542A2 (de) 1998-07-07 1999-07-02 Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum

Publications (1)

Publication Number Publication Date
NZ509729A true NZ509729A (en) 2003-06-30

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ509729A NZ509729A (en) 1998-07-07 1999-07-02 Agents with an antidepressive effect

Country Status (32)

Country Link
US (1) US6255329B1 (https=)
EP (1) EP1093369B1 (https=)
JP (1) JP2002520273A (https=)
KR (1) KR100557692B1 (https=)
CN (1) CN1230168C (https=)
AR (1) AR019896A1 (https=)
AT (1) ATE228365T1 (https=)
AU (1) AU762128B2 (https=)
BG (1) BG64972B1 (https=)
BR (1) BR9911768A (https=)
CA (1) CA2336833C (https=)
CZ (1) CZ294087B6 (https=)
DE (2) DE19830201A1 (https=)
DK (1) DK1093369T3 (https=)
EA (1) EA003142B1 (https=)
EE (1) EE04296B1 (https=)
ES (1) ES2183583T3 (https=)
HU (1) HUP0103922A3 (https=)
ID (1) ID27776A (https=)
IL (1) IL140603A0 (https=)
MY (1) MY117969A (https=)
NO (1) NO20010064L (https=)
NZ (1) NZ509729A (https=)
PL (1) PL195043B1 (https=)
PT (1) PT1093369E (https=)
RS (1) RS49795B (https=)
SK (1) SK284923B6 (https=)
TR (1) TR200100146T2 (https=)
TW (1) TW592698B (https=)
WO (1) WO2000002542A2 (https=)
YU (1) YU401A (https=)
ZA (1) ZA200100090B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
WO2005070428A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
EP2341912B1 (en) 2008-09-05 2014-01-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (adhd)
JP2012525426A (ja) * 2009-04-30 2012-10-22 スパーナス ファーマシューティカルズ インコーポレイテッド うつ病を治療する方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
AU2013217013B2 (en) 2012-02-08 2017-04-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
IL312486B2 (en) * 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
NZ325914A (en) * 1996-03-29 1999-09-29 Pfizer Benzyl(idene)-lactam derivatives and salts thereof, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors and thus are effective as psychotherapeutic agents
ATE282417T1 (de) * 1996-12-02 2004-12-15 Merck Sharp & Dohme Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
EA200100084A1 (ru) 2001-08-27
KR20010079491A (ko) 2001-08-22
IL140603A0 (en) 2002-02-10
BG64972B1 (bg) 2006-11-30
RS49795B (sr) 2008-06-05
BR9911768A (pt) 2001-04-03
EP1093369B1 (de) 2002-11-27
ID27776A (id) 2001-04-26
CA2336833A1 (en) 2000-01-20
PL345842A1 (en) 2002-01-14
CZ294087B6 (cs) 2004-10-13
HUP0103922A2 (hu) 2002-03-28
EA003142B1 (ru) 2003-02-27
EE200100014A (et) 2002-06-17
WO2000002542A3 (de) 2000-06-22
KR100557692B1 (ko) 2006-03-07
HUP0103922A3 (en) 2002-08-28
CN1230168C (zh) 2005-12-07
EE04296B1 (et) 2004-06-15
TR200100146T2 (tr) 2001-07-23
CZ200177A3 (en) 2001-06-13
SK284923B6 (sk) 2006-02-02
ZA200100090B (en) 2002-04-04
ATE228365T1 (de) 2002-12-15
WO2000002542A2 (de) 2000-01-20
AU5030399A (en) 2000-02-01
NO20010064D0 (no) 2001-01-05
SK112001A3 (en) 2001-10-08
DE59903556D1 (de) 2003-01-09
DK1093369T3 (da) 2002-12-16
AU762128B2 (en) 2003-06-19
CN1308533A (zh) 2001-08-15
AR019896A1 (es) 2002-03-20
CA2336833C (en) 2008-09-23
BG105112A (bg) 2001-10-31
JP2002520273A (ja) 2002-07-09
PL195043B1 (pl) 2007-08-31
YU401A (sh) 2003-10-31
ES2183583T3 (es) 2003-03-16
PT1093369E (pt) 2003-03-31
TW592698B (en) 2004-06-21
US6255329B1 (en) 2001-07-03
EP1093369A2 (de) 2001-04-25
MY117969A (en) 2004-08-30
HK1037976A1 (en) 2002-03-01
NO20010064L (no) 2001-03-02
DE19830201A1 (de) 2000-01-13

Similar Documents

Publication Publication Date Title
NZ509729A (en) Agents with an antidepressive effect
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
GB0025173D0 (en) Therapeutic agents
MXPA03007140A (es) Derivados de carbolina.
EP1139753A4 (en) PREPARATIONS FOR THE TREATMENT OF DISEASES AND METHODS RELATED THERETO
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
IL108845A0 (en) Use of anticonvulsants in the treatment of neuro-aids
DE59914814D1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
ATE237680T1 (de) Transplantation von hämatopoietischen zellen
NO20005290D0 (no) Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom
YU47809B (sr) Novi ergolin-8-karboksamidi i postupak za njihovo dobijanje
DK1392355T3 (da) Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
MX344589B (es) Instrumento para el cuidado oral que incluye un agente para el cuidado oral.
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
IL143280A0 (en) Use of riluzole for treating acoustic traumas
GB9802542D0 (en) New use
FR2815042B1 (fr) Utilisation d'une composition a activite antioxydante pour le conditionnement de cellules souches
AU7419501A (en) Use of riluzole or its salts for preventing and treating adrenoleukodystrophy
IT1317331B1 (it) Procedimento per la realizzazione di plantari anatomici perfezionati emezzi per l'attuazione del procedimento.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)